REGENXBIO Inc

REGENXBIO insider sale: 4,700 shares sold for tax reasons amid an FDA pause on its Hurler‑syndrome program—minor move but raises investor caution and market volatility.

Insider buying shows confidence in REGENXBIO’s gene‑therapy future despite FDA setbacks – investors see a potential rebound once regulatory hurdles are cleared.